Renascience Past Earnings Performance
Past criteria checks 0/6
Renascience's earnings have been declining at an average annual rate of -15.4%, while the Pharmaceuticals industry saw earnings growing at 5.6% annually. Revenues have been growing at an average rate of 4.3% per year.
Key information
-15.4%
Earnings growth rate
-9.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 3.4% |
| Revenue growth rate | 4.3% |
| Return on equity | -16.1% |
| Net Margin | -133.0% |
| Next Earnings Update | 08 Aug 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Renascience makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 194 | -258 | 417 | 0 |
| 31 Dec 23 | 190 | -331 | 245 | 235 |
| 30 Sep 23 | 200 | -277 | 201 | 235 |
| 30 Jun 23 | 173 | -270 | 193 | 235 |
| 31 Mar 23 | 100 | -335 | 185 | 235 |
| 31 Dec 22 | 103 | -316 | 250 | 82 |
| 30 Sep 22 | 128 | -288 | 245 | 82 |
| 30 Jun 22 | 128 | -285 | 218 | 82 |
| 31 Mar 22 | 139 | -254 | 193 | 82 |
| 31 Mar 21 | 209 | -100 | 265 | 0 |
| 31 Mar 20 | 72 | -184 | 235 | 0 |
Quality Earnings: 4889 is currently unprofitable.
Growing Profit Margin: 4889 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4889 is unprofitable, and losses have increased over the past 5 years at a rate of 15.4% per year.
Accelerating Growth: Unable to compare 4889's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4889 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (13.3%).
Return on Equity
High ROE: 4889 has a negative Return on Equity (-16.06%), as it is currently unprofitable.